Deal Globally, Treat Locally: Serono Buys Rights to InDex's Kappaproct
Executive Summary
In-licensing Phase II ulcerative colitis drug Kappaproct from Swedish biotech InDex Pharmaceuticals wasn't the major move observers have been waiting for from Serono; it certainly doesn't reduce the Swiss firm's dependence on Rebif. But the $35 million deal endorses InDex's localized approach to antisense therapy, a failure-ridden area that many firms have given up on.